still appeal upsid medium
quarter contain number on-going challeng largest
push-out re-ramp pharmedium chang along
on-going headwind led guidanc consensu estim well
concern time compound busi re-ramp full product
ultim think matter time rather perman impair
clearli recogn profit headwind creat one potenti bright spot
call optimist commentari around gener echo commentari
channel particip gener deflat start see true improv trend could
serv profit off-set pharmedium headwind reiter buy rate
still think compani steadi growth within core under-util
current balanc sheet reduc price object po
target price-to-earnings
ep reduc pharmedium recoveri push-out
reduc ep ep
reduct includ on-going pressur busi well
elong pharmedium clinic issu hamper pharma segment profit
growth would also note full disclosur remov opioid-
relat litig cost in-lin compani recogn peer
includ cost appli would repres somewher
rang depend whether entireti litig cost tie
opioid remov would make current multipl stock higher
upcom event catalyst
rest distributor import near-term data point
brand price increas particularli januari addit on-going
pharmedium headwind clariti segment busi remedi
effort key investor sentiment final look forward upcom
investor meet manag dive busi
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest drug distributor us
sizabl global gener sourc joint ventur
partnership
anim health unit oper
companion product anim distribut
transport logist technolog
compani base chesterbrook pa
buy rate driven long-term cash flow
gener stori trade larger-than-
expect discount rel histor averag
although premium relat potenti
deal appear remov share
think steadi revenu gener
provid solid core ebit growth even
headwind pricing/volum given
histor activ expect compani
like continu deploy toward
renew humana other without creat margin headwind
specialti report consecut quarter revenu growth
pharmedium lash
lash continu migrat fusion technolog platform
feedback posit
continu commun fda
made progress memphi taken longer
expect
tim guttman decid retir
gross profit growth outsid brazil would ex-brazil one-tim
brazil contribut half opex growth
hd smith grew roughli opex growth
sg growth ex-brazil hd smith would
revenu growth would ex-brazil
growth growth specialti distribut
high-teen integr hd smith
impact pharmedium
on-going remedi memphi facil
halfway year growth second half end
middl guidanc rang
finish higher
deflat rate remain stabl improv versu last year
brand inflat mid-singl digit believ rang within
reason base histor price practic
brand buy-sid compens cover fee
servic
compens realiz part
recent manufactur ration manufactur
launch certain anda
expect gener price similar tail end
longer break gener deflat someth
compani updat
stabil benefit margin cash flow hope
begin stabil
driven broad portfolio custom multipl strateg
sourc team help stay competit
off-set lower volum pharmedium particularli
first half
expect grow mid-singl digit rang
expect hit run-rat hd smith synergi
grow low-to-mid-singl digit
return growth segment
pharma distribut memphi facil remain close
work reopen current expect segment
oper grow low singl mid-singl digit rang
without pharmedium headwind pharma ebit would
grow mid-singl digit rang
pharmedium three scenario
memphi growth rate market
chang relat abc convers fda
commit work fda restart
get feedback
headwind besid pharmedium
pharmedium biggest thing move us guidanc rang
busi perform hd smith synergi manag opex
factor
remain confid long-term model
portfolio ration impact gener part part
see stabil gener
regard part remain commit commun
commun set show growth year
believ retain unit econom face price cut brand
confid econom receiv fair
abc differenti price strategi inning compani
compani well halfway
brand inflat mid-singl digit thought
inflat would surpris environ
adjust opioid expens
expens normal cours busi
price object base ep multipl
five-year averag five-year high although would argu
artifici high due period gener inflat also repres similar
discount vs last five year think discount warrant given
incorpor modest growth slowdown seen rest suppli
chain well encompass competit risk
downsid risk po increment wors drug price pressur increas
competit creat gross profit headwind risk amazon anoth disrupt
forc enter suppli chain market lack avail attract capit deploy
opportun fluctuat relat press report hypothet
acquisit upsid risk potenti volum pickup increas
buyside/sellsid spread opportun cost save
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
